Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.

Published byLeslie Henderson Modified over 4 years ago

Similar presentations

Presentation on theme: "Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated."— Presentation transcript:

1 Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors.
In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. (A) An increased CD4+CD25+Foxp3+ Treg population among CD4 T cells was observed in tumors (LL/2-luc or MC38-luc) compared to that in the spleen (n = 3) (*P < 0.001, **P < versus control, one-way ANOVA with Dunnett’s test). (B) Regimen used for local NIR-PIT. (C) In vivo BLI is shown for tumor-bearing mice that were untreated, received control-F(ab′)2–IR700 followed by NIR-PIT, received CD25-F(ab′)2–IR700 alone, or treated with local CD25-targeted NIR-PIT. Before NIR-PIT, tumors sizes were equivalent, exhibiting similar bioluminescence, but only the CD25-targeted NIR-PIT group showed a decrease in BLI. iv, intravenously. (D) Quantitative relative light units (RLU) (before PIT is set to 100) showed a significant RLU decrease in the experimental tumors [n = 6 mice in each group; *P = (day 1) and (day 2), PIT versus control, Tukey’s test with ANOVA]. (E) Local CD25-targeted NIR-PIT reduced tumor volume (n = 8 mice in each group; *P < , PIT versus others, Tukey’s test with ANOVA). Treatment schedule indicated below the graph corresponds to that in (B). (F) Local CD25-targeted NIR-PIT prolonged the survival of the mice (n = 8 mice in each group; *P < , PIT versus control, log-rank test and Wilcoxon test). (G) The body weight of mice not receiving CD25-targeted NIR-PIT gradually increased because of tumor growth, in contrast to the PIT group showing negligible body weight increase (n = 8 mice in each group) (*P = , PIT versus control at day 14). (H) Local CD25-targeted NIR-PIT resulted in a depletion of CD4+CD25+Foxp3+ Tregs in tumors, but not in the spleen (n = 5) (*P < 0.008, Mann-Whitney test; P = ns, Mann-Whitney test). (I) Local CD25-targeted NIR-PIT did not significantly affect the number of CD8 T cells (CD3+CD8+) or NK cells (CD3−NK1.1+) (n = 5; P = ns, Mann-Whitney test). Kazuhide Sato et al., Sci Transl Med 2016;8:352ra110 Copyright © 2016, American Association for the Advancement of Science

Download ppt "Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated."

Similar presentations

Targeting Improves MSC Treatment of Inflammatory Bowel Disease

Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Targeting Improves MSC Treatment of Inflammatory Bowel Disease

Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.
Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,
Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.
Fig. 4. In vivo analysis of slpA mutant in the Syrian Golden hamster.

Fig. 4. In vivo analysis of slpA mutant in the Syrian Golden hamster.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Specific depletion of CD4-DTR–derived CD4 T cells.

Specific depletion of CD4-DTR–derived CD4 T cells.
Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.
Volume 26, Issue 2, Pages (February 2018)

Volume 26, Issue 2, Pages (February 2018)
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
Volume 18, Issue 9, Pages (September 2010)

Volume 18, Issue 9, Pages (September 2010)
Fig. 5 Local gel scaffold for T cell memory response.

Fig. 5 Local gel scaffold for T cell memory response.

Similar presentations

Ads by Google